RT Journal Article
T1 Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.
A1 Dominguez-Mozo, Maria Inmaculada
A1 Perez-Perez, Silvia
A1 Villar, Luisa Maria
A1 Oliver-Martos, Begoña
A1 Villarrubia, Noelia
A1 Matesanz, Fuencisla
A1 Costa-Frossard, Lucienne
A1 Pinto-Medel, Maria Jesus
A1 Garcia-Sanchez, Maria Isabel
A1 Ortega-Madueño, Isabel
A1 Lopez-Lozano, Lorena
A1 Garcia-Martinez, Angel
A1 Izquierdo, Guillermo
A1 Fernandez, Oscar
A1 Alvarez-Cermeño, Jose Carlos
A1 Arroyo, Rafael
A1 Alvarez-Lafuente, Roberto
K1 Adult
K1 Antibody Formation
K1 Biomarkers, Pharmacological
K1 Capsid Proteins
K1 Disease Progression
AB There are an increasing number of treatments available for multiple sclerosis (MS). The early identification of optimal responders to individual treatments is important to achieve individualized therapy. With this aim, we performed a multicenter retrospective longitudinal study including 186 MS patients treated with natalizumab who were followed for 2 years. We analyzed the following variables at recruitment: sex, current age, age at disease onset, disease duration, EDSS, number of T2 and Gd + lesions, IgG and IgM oligoclonal bands, HLA class II (DR, DRB, DQA, DQB, and DRB1*15:01), IgG and IgM antibody titers against human herpesvirus 6 (HHV-6) and the antibody response to Epstein-Barr virus (EBV) through the measurement of the anti-EBNA-1 and anti-VCA IgG titers, in relation to clinical response (no relapses or disability progression), and to NEDA-3 (no evidence of disease activity in terms of clinical response and no changes in MRI scans either) after 2-years follow-up. Baseline EDSS score, baseline EBNA-1 IgG titers and percentage change of HHV6 IgG titers between baseline and 6 month visits were significantly different in clinical responders and in NEDA-3 status (all of them remained significant in the multivariate analysis). We identified three variables for the early identification of natalizumab optimal responders in a rapid and cost-effective approach.
PB Nature Publishing Group
YR 2020
FD 2020-06-17
LK http://hdl.handle.net/10668/16172
UL http://hdl.handle.net/10668/16172
LA en
NO Dominguez-Mozo MI, Perez-Perez S, Villar LM, Oliver-Martos B, Villarrubia N, Matesanz F, Costa-Frossard L, Pinto-Medel MJ, García-Sánchez MI, Ortega-Madueño I, et al. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Sci Rep. 2020 Aug 28;10(1):14244
DS RISalud
RD Apr 12, 2025